Local Coverage DeterminationClinical Laboratory

LCD L36353: Lab: Special Histochemical Stains and Immunohistochemical Stains — Noridian

LCD-L36353

Document details

Document type
Local Coverage Determination
Issuing body
MAC Contractor
Document ID
LCD-L36353
Published
June 5, 2026
Effective date
November 2, 2025
MAC region
Noridian

Summary

The new LCD on Special Histochemical and Immunohistochemical Stains is likely to impact lab billing practices significantly by specifying the criteria for coverage. Providers should ensure that their

New LCD impacts lab billing for histochemical stains.

Affected codes

ICD-10-CM

Affected specialty

Clinical Laboratory alerts →

Source document

https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=36353&ver=38

CLV Intelligence summarizes publicly available federal publications. Not affiliated with or endorsed by any government agency.

Related alerts

4

CMS Transmittal R13849CP: Changes to the Laboratory National Coverage Determination (NCD) Edit Software for October 2026…

Policy CMS-T-R13849CP · Clinical Laboratory

Critical

CMS is updating the Laboratory NCD Edit Software effective October 5, 2026, to reflect changes in National Coverage Determinations for lab services. Billing teams must review updated NCD edits in thei

View alert

CMS Transmittal R13855CP: July 2026 Quarterly Update to the Clinical Laboratory Fee Schedule (CLFS) and Clinical…

Policy CMS-T-R13855CP · Clinical Laboratory

Critical

This transmittal implements the July 2026 quarterly update to the Clinical Laboratory Fee Schedule (CLFS), effective July 6, 2026. Billing teams must update their lab fee schedule tables to reflect th

View alert

LCD L39044: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing — WPS

Policy LCD-L39044 · Clinical Laboratory

High

The LCD L39044 focuses on coverage for molecular syndromic panels for infectious disease pathogen identification. As a final LCD, it is currently active and will be effective starting June 25, 2026, i

View alert

LCD L40272 (Notice Ends 08/09/2026): MolDX: Biomarker Testing in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis — WPS

Policy LCD-L40272 · Clinical Laboratory

Critical

LCD L40272 establishes coverage criteria for MolDX biomarker testing in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH), ef

View alert